Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.

Overexpression of p53 is found in approximately 50% of human cancers, making it an attractive target antigen for immunotherapy of cancer. Research in this area has thus far primarily focused on p53-specific CTLs. Although these CTLs were shown to be highly effective against p53-overexpressing tumors in vivo, immunological tolerance seems to strongly restrict the spectrum of the p53-specific CTL repertoire in p53(+/+) subjects. In view of the emerging role of CD4(+) Th (Th) cells in the antitumor response, we investigated the specificity and antitumor efficacy of the p53-specific Th response in mice. Our data show that high affinity Th cells against the naturally processed epitope p53(108-122) can be elicited in both p53(-/-) and p53(+/+) mice, indicating that the p53-specific T-cell response is not affected by tolerance at the Th level. Furthermore, p53(108-122)-specific Th cells were effective in enabling p53-specific CTLs to control the growth of p53-overexpressing tumors in vivo. Therefore, exploitation of the p53-specific Th response appears to be a highly useful aspect of immunotherapeutic strategies against cancers.

[1]  C. Melief,et al.  Antigen-Antibody Immune Complexes Empower Dendritic Cells to Efficiently Prime Specific CD8+ CTL Responses In Vivo1 , 2002, The Journal of Immunology.

[2]  J. Gribben,et al.  Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. , 2001, Cancer research.

[3]  Javier Hernández,et al.  CTLA-4 Blockade Enhances the CTL Responses to the p53 Self-Tumor Antigen1 , 2001, The Journal of Immunology.

[4]  S. H. van der Burg,et al.  Long lasting p53‐specific T cell memory responses in the absence of anti‐p53 antibodies in patients with resected primary colorectal cancer , 2001, European journal of immunology.

[5]  R. Offringa,et al.  High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. , 2000, Cancer research.

[6]  D. Smith,et al.  CD40 activation enhances the magnitude of cellular immune responses against p53 but not the avidity of the effectors , 2000, Cancer Immunology, Immunotherapy.

[7]  Y. Shyr,et al.  Induction of cytotoxic T cells and their antitumor activity in mice transgenic for carcinoembryonic antigen , 2000, Cancer Immunology, Immunotherapy.

[8]  Santa Jeremy Ono,et al.  CD4+ T Cell Responses to Self- and Mutated p53 Determinants During Tumorigenesis in Mice1 , 2000, The Journal of Immunology.

[9]  S. H. van der Burg,et al.  p53: A Potential Target Antigen for Immunotherapy of Cancer , 2000, Annals of the New York Academy of Sciences.

[10]  J. Drijfhout,et al.  Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. , 2000, Protein expression and purification.

[11]  Mark M. Davis,et al.  The Use of HLA A2.1/p53 Peptide Tetramers to Visualize the Impact of Self Tolerance on the TCR Repertoire1 , 2000, The Journal of Immunology.

[12]  Margaret Ashcroft,et al.  Regulation of p53 stability , 1999, Oncogene.

[13]  D. Metzger,et al.  CD4+ and CD8+ T-cell clones from congenital rubella syndrome patients with IDDM recognize overlapping GAD65 protein epitopes. Implications for HLA class I and II allelic linkage to disease susceptibility. , 1999, Human immunology.

[14]  Ferry Ossendorp,et al.  CD4 T Cells and Their Role in Antitumor Immune Responses , 1999, The Journal of experimental medicine.

[15]  P. Ricciardi-Castagnoli,et al.  Fcγ Receptor–mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I–restricted Antigen Presentation after Immune Complex Internalization , 1999, The Journal of experimental medicine.

[16]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[17]  D. Pardoll,et al.  The role of CD4+ T cell responses in antitumor immunity. , 1998, Current opinion in immunology.

[18]  R. Offringa,et al.  Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes. , 1998, Cancer research.

[19]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[20]  Richard A. Flavell,et al.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.

[21]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[22]  C. Melief,et al.  Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors , 1998, The Journal of experimental medicine.

[23]  H. Saya,et al.  Evidence that HLA class II‐restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms , 1998, European journal of immunology.

[24]  J. Tartaglia,et al.  The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity. , 1998, Vaccine.

[25]  M. Lotze,et al.  Genetically modified bone marrow‐derived dendritic cells expressing tumor‐associated viral or “self” antigens induce antitumor immunity in vivo , 1997, European journal of immunology.

[26]  G. Fleuren,et al.  Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes , 1997, The Journal of experimental medicine.

[27]  J. Drijfhout,et al.  Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes. , 1997, Cancer letters.

[28]  P. Ricciardi-Castagnoli,et al.  Dendritic cell maturation is required for initiation of the immune response , 1997, Journal of leukocyte biology.

[29]  M. Theobald,et al.  Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes , 1997, The Journal of experimental medicine.

[30]  S. H. van der Burg,et al.  Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). , 1997, Human immunology.

[31]  Francesca Granucci,et al.  Maturation Stages of Mouse Dendritic Cells in Growth Factor–dependent Long-Term Cultures , 1997, The Journal of experimental medicine.

[32]  L. Fugger,et al.  Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Bourhis,et al.  Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. , 1996, Journal of the National Cancer Institute.

[34]  A. Lanzavecchia,et al.  Mechanisms of antigen uptake for presentation. , 1996, Current opinion in immunology.

[35]  N. Braunstein,et al.  Determination of the allele‐specific antigen‐binding site on I‐Ak and I‐Ab molecules , 1996, European journal of immunology.

[36]  E. Paoletti,et al.  p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  H. Sakamoto,et al.  Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines , 1996, The Journal of experimental medicine.

[38]  C. Partidos,et al.  Induction of measles virus‐specific cytotoxic T‐cell responses after intranasal immunization with synthetic peptides , 1996, Immunology.

[39]  S. H. van der Burg,et al.  Antibodies against p53 are associated with poor prognosis of colorectal cancer. , 1995, British Journal of Cancer.

[40]  T. Soussi,et al.  Serum p53 antibodies as early markers of lung cancer , 1995, Nature Medicine.

[41]  J. Bonneterre,et al.  Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer , 1995, The Lancet.

[42]  P. Laurent-Puig,et al.  Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. , 1995, Gut.

[43]  S. H. van der Burg,et al.  p53, a potential target for tumor-directed T cells. , 1994, Immunology letters.

[44]  J. Berzofsky,et al.  Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. , 1994, Journal of immunology.

[45]  M. Feltkamp,et al.  Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells , 1993, European journal of immunology.

[46]  S. H. van der Burg,et al.  In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 , 1993, European journal of immunology.

[47]  D. Thomson,et al.  Analysis of the anti-p53 antibody response in cancer patients. , 1993, Cancer research.

[48]  J. Berzofsky,et al.  A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. , 1993, Cancer research.

[49]  D. Lane,et al.  The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. , 1992, Cancer research.

[50]  Charles A. Janeway,et al.  Truncation variants of peptides isolated from MHC class II molecules suggest sequence motifs , 1992, Nature.

[51]  J. Minna,et al.  Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. , 1992, Cancer research.

[52]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[53]  I. Frazer,et al.  A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[54]  P. Greenberg Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.

[55]  J. Berzofsky,et al.  An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class II-restricted help for itself , 1990, The Journal of experimental medicine.

[56]  R. Coffman,et al.  The Role of Helper T Cell Products in Mouse B Cell Differentiation and Isotype Regulation , 1988, Immunological reviews.

[57]  W. Kast,et al.  Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. Protection by T cells is MHC- restricted and MHC-regulated; a model for MHC-disease associations , 1986, The Journal of experimental medicine.